Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 13, 2025
Deals
Seeing high potential for antipsychotic, J&J buys Intra-Cellular for $14.6B
Continued appetite for neuroscience assets drives deal; pharma rebuilding in an area where it has become less reliant in recent years
BioCentury | Sep 13, 2024
Finance
Public Equity Report: Biotech quintet raises $1.3B+ via follow-ons
Ionis tops list of five biotechs raising at least $200M in public offerings, along with Centessa, Viridian, Relay and Xencor; plus PIPEs keep flowing
BioCentury | Sep 12, 2024
Product Development
Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd
Plus: Results from Relay, Centessa, Viridian, Amgen and more
BioCentury | Sep 4, 2024
Discovery & Translation
The inextricable linkage of biomarkers and target discovery
Back to School 2024: How biomarkers can help validate targets while bringing precision medicine to I&I and neurology
BioCentury | May 30, 2024
Product Development
Clinical Report: Phase III win for J&J in neuropsychiatry; Biohaven falls on BHV-1300 data
Plus: Insmed gets boost from bronchiectasis readout and updates from HI-Bio, Corcept, Tango and Ikena
BioCentury | Apr 27, 2024
Finance
Public equity report: Cidara resets with $240M PIPE
Plus: Centessa raises $100M in first follow-on since 2021 IPO
BioCentury | Feb 14, 2024
Product Development
Clinical report: Data from Gilead, KalVista, Takeda, Synlogic and AN2
What Gilead’s CD47 failure means for the class; KalVista to submit HAE program; Takeda advances narcolepsy therapy; and more
BioCentury | May 26, 2023
Product Development
Three roads to precision neuropsychiatry, says Manji
The U.K. launches its Mental Health Mission, naming former J&J exec Husseini Manji as chair
BioCentury | Nov 16, 2022
Deals
Nov. 16 Quick Takes: Simcere, Idorsia in China deal for insomnia drug
Plus: Fundings for Haystack, Natera and SynRx; Ardelyx’s FDA panel; Mineralys’ hypertension readout; and Roche’s monkeypox EUA
BioCentury | Oct 20, 2021
Product Development
Oct. 19 Quick Takes: Tymlos, vonoprazan and Tyvyt meet in Phase III
Plus Orexia, LogicBio, Esperion, MilliporeSigma and Intrivo
Items per page:
1 - 10 of 59